DRD3
ENSG00000151577
Target class
GPCR
Chromosome
3
Approved drugs
30
Clinical candidates (approved and in development)
38
- Approved drugs
- 30
- Clinical candidates (approved and in development)
- 38
- Chemical probe available
- Yes
- Target name
- DRD3
- Gene name
- Dopamine receptor D3
- Gene symbol
- DRD3
- Protein name
- D(3) dopamine receptor (Dopamine D3 receptor)
- Gene biotype
- Protein coding
- Gene family
- Dopamine receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 2
- Highest tissue expression
- 2.95
- Tissue specificity (Gini)
- 0.954
- Tissue specificity (tau)
- 0.987
- KEGG gene identifiers
- hsa:1814
- Protein interaction confidence
- 0.805048
- Protein interaction partners
- 21
- R-HSA-390651
- R-HSA-418594
- End position
- 114199407
- Start position
- 114127580
- Chromosome
- 3
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein . Note=Both membrane-bound and scattered in the cytoplasm during basal conditions. Receptor stimulation results in the rapid internalization and sequestration of the receptors at the perinuclear area (5 and 15 minutes), followed by the dispersal of the receptors to the membrane (30 minutes). DRD3 and GRK4 co-localize in lipid rafts of renal proximal tubule cells.
Publication evidence
- PubMed 19520868
- Tissue specificity (tau)
- 0.987144
- Expression inequality (Gini)
- 0.953554
Expression in transcripts per million
- Brain - Nucleus accumbens (basal ganglia)
- 2.95
- Testis
- 1.06
- Brain - Caudate (basal ganglia)
- 0.47
- Brain - Putamen (basal ganglia)
- 0.36
- Brain - Hypothalamus
- 0.05
Expression in transcripts per million
- Brain - Nucleus accumbens (basal ganglia)2.95
- Testis1.06
- Brain - Caudate (basal ganglia)0.47
- Brain - Putamen (basal ganglia)0.36
- Brain - Hypothalamus0.05
- Spleen0.02
- Brain - Frontal Cortex (BA9)0.02
- Brain - Cortex0.01
- Brain - Anterior cingulate cortex (BA24)0.01
- Kidney - Medulla0.01
- Artery - Aorta0
- Adipose - Visceral (Omentum)0
- Whole Blood0
- Brain - Cerebellum0
- Ovary0
- Nerve - Tibial0
- Artery - Tibial0
- Brain - Substantia nigra0
- Cervix - Ectocervix0
- Adipose - Subcutaneous0
- Cells - Cultured fibroblasts0
- Breast - Mammary Tissue0
- Cervix - Endocervix0
- Esophagus - Gastroesophageal Junction0
- Brain - Hippocampus0
And 29 more, listed on the interactive page.
- GO:0002031
- GO:0006874
- GO:0007186
- GO:0007191
- GO:0007195
- GO:0032467
- GO:0034776
- GO:0042220
- GO:0042417
- GO:0048148
- GO:0050482
- GO:0050709
- GO:0051584
- GO:0060134
Cellular components
- GO:0005886
- GO:0001591
- GO:0005515
role in facilitating drug addiction/dependence
Effects
- Activation/Increase/Upregulation
Studies
- preclinical
Biological samples
- CNS
PubMed 38773351Severe akathisia
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- CNS
PubMed 38773351nausea
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
PubMed 38773351Facilitate reward reinforcement
Effects
- Activation/Increase/Upregulation
Studies
- preclinical
Biological samples
- CNS
PubMed 38773351insomnia
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- CNS
PubMed 38773351
Related records
Trials (1,308)
- "Extended" (Alternate Day) Antipsychotic Dosing
- "Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"
- 1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study)
- 12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome
- 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
- 3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)
- 3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)
- 40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)
- 5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia
- 5HT3 Antagonism and Auditory Gating in Schizophrenia
- 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)
- 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)
- 9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)
- A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period
- A 4-week, Randomized, Rater-blinded, Parallel Study to Evaluate Quetiapine in Improving Sleep Quality of Schizophrenia
- A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia
- A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS
- A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes
- A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features
- A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS)
Drugs (48)
- ABT-925 Dopamine D3 receptor antagonist
- Adoprazine Dopamine D3 receptor antagonist
- Amisulpride Dopamine receptors; D2 & D3 antagonist
- Amoxapine Dopamine receptor antagonist
- Apomorphine D2-like dopamine receptor agonist
- Apomorphine hydrochloride D2-like dopamine receptor agonist
- Blonanserin Dopamine D3 receptor antagonist
- Bromocriptine D2-like dopamine receptor agonist
- Bromocriptine mesylate D2-like dopamine receptor agonist
- Cariprazine Dopamine D3 receptor modulator
- Cariprazine hydrochloride Dopamine D3 receptor modulator
- Chlorpromazine D2-like dopamine receptor antagonist
- Chlorpromazine hydrochloride D2-like dopamine receptor antagonist
- Chlorprothixene Dopamine D3 receptor antagonist
- Droperidol D2-like dopamine receptor antagonist
- Ergoloid Dopamine receptor agonist
- Ergoloid mesylates Dopamine receptor agonist
- Etilevodopa Dopamine D3 receptor agonist
- Haloperidol D2-like dopamine receptor inverse agonist
- Haloperidol decanoate D2-like dopamine receptor inverse agonist